These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 24153411)

  • 1. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
    Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
    JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
    Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
    JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
    Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
    Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing opioid withdrawal during double-blind buprenorphine detoxification.
    Dunn KE; Saulsgiver KA; Miller ME; Nuzzo PA; Sigmon SC
    Drug Alcohol Depend; 2015 Jun; 151():47-55. PubMed ID: 25823907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study.
    Sigmon SC; Dunn KE; Badger GJ; Heil SH; Higgins ST
    Addict Behav; 2009 Mar; 34(3):304-11. PubMed ID: 19081679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
    Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
    JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
    Lofwall MR; Walsh SL; Nunes EV; Bailey GL; Sigmon SC; Kampman KM; Frost M; Tiberg F; Linden M; Sheldon B; Oosman S; Peterson S; Chen M; Kim S
    JAMA Intern Med; 2018 Jun; 178(6):764-773. PubMed ID: 29799968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous reductions in smoking during double-blind buprenorphine detoxification.
    Patrick ME; Dunn KE; Badger GJ; Heil SH; Higgins ST; Sigmon SC
    Addict Behav; 2014 Sep; 39(9):1353-6. PubMed ID: 24845165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
    Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
    JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults.
    Marsch LA; Moore SK; Borodovsky JT; Solhkhah R; Badger GJ; Semino S; Jarrett K; Condon KD; Rossettie K; Vincent P; Hajizadeh N; Ducat E
    Addiction; 2016 Aug; 111(8):1406-15. PubMed ID: 26918564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine tapering schedule and illicit opioid use.
    Ling W; Hillhouse M; Domier C; Doraimani G; Hunter J; Thomas C; Jenkins J; Hasson A; Annon J; Saxon A; Selzer J; Boverman J; Bilangi R
    Addiction; 2009 Feb; 104(2):256-65. PubMed ID: 19149822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The multi-site prescription opioid addiction treatment study: 18-month outcomes.
    Potter JS; Dreifuss JA; Marino EN; Provost SE; Dodd DR; Rice LS; Fitzmaurice GM; Griffin ML; Weiss RD
    J Subst Abuse Treat; 2015 Jan; 48(1):62-9. PubMed ID: 25189089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users.
    Nielsen S; Hillhouse M; Thomas C; Hasson A; Ling W
    J Addict Med; 2013; 7(1):33-8. PubMed ID: 23222095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers.
    Meyer AC; Miller ME; Sigmon SC
    Addict Behav; 2015 Mar; 42():189-93. PubMed ID: 25481453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
    Murphy SM; McCollister KE; Leff JA; Yang X; Jeng PJ; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
    Ann Intern Med; 2019 Jan; 170(2):90-98. PubMed ID: 30557443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.
    Woodcock EA; Lundahl LH; Greenwald MK
    Drug Alcohol Depend; 2015 Jan; 146():89-96. PubMed ID: 25479914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.